CSI Laboratories

What CSI Laboratories does

CSI Laboratories, founded in 1997 and headquartered in Alpharetta, Georgia, is a specialty pathology and cancer diagnostics laboratory that now operates under the Fulgent Oncology brand following a 2024 rebrand by parent company Fulgent Genetics (NASDAQ: FLGT). The company provides precision-medicine cancer diagnostics to healthcare providers — including oncologists, pathologists, hospitals, and cancer care teams — as well as to patients, offering a comprehensive genomic testing portfolio under its proprietary Lumera® product line. Tests cover solid tumor profiling (Lumera Xpanded Profile, Lumera NGS Profile, Lumera Liquid Biopsy), hematopathology evaluation (Lumera Comprehensive Hematological Evaluation, Lumera Heme NGS Profile), HRR-HRD molecular profiling for targeted therapy selection, and hereditary cancer risk assessment.

The underlying technical platform combines next-generation sequencing (NGS) with machine learning capabilities, paired with full clinical case review by medical experts. The company operates with 101-250 employees and is co-located under the Fulgent Oncology umbrella with sister company Inform Diagnostics, a fellow Fulgent Genetics subsidiary, providing what the company describes as more than 50 years of combined pathology experience. CSI Laboratories is HIPAA-compliant and likely holds CLIA/CAP accreditations typical of U.S. clinical laboratories, though specific accreditations are not enumerated in available materials.

The business model is a fee-for-service clinical laboratory, generating revenue per test on a pay-as-you-go billing cadence through direct B2B sales to healthcare institutions and oncology practices, with distribution channels including phone (1-888-354-8168), email, and authenticated client portals. Pricing is not publicly disclosed and is determined per test/profile, varying by insurance coverage, institutional contracts, and test specifications. As a wholly-owned subsidiary of publicly-traded Fulgent Genetics, CSI Laboratories benefits from the parent's broader genomics, bioinformatics, and artificial intelligence infrastructure, but standalone financials are not separately reported.

Name

CSI Laboratories

Website

https://csilaboratories.com

Company type

Private

Founded year

1997

Operating status

Operating

Headcount range

101–250 employees

Short description

CSI Laboratories (now Fulgent Oncology) is a U.S.-based specialty cancer diagnostics laboratory, subsidiary of Fulgent Genetics, offering NGS-based solid tumor, hematopathology, liquid biopsy, and hereditary cancer testing to oncologists, pathologists, and patients via a fee-for-service B2B model.

Ownership category

akta.pro rank

Product category

Cancer Diagnostic Services

NAICS

Medical Laboratories (621511)

SIC

Services-Medical Laboratories (8071)

akta.pro primary industry

Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE)

akta.pro secondary industries

Molecular Diagnostics (PCR/qPCR, NGS-based assays) (HLAAALAA), Reference & Esoteric Testing Laboratories (HLAFAMAJ), Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC), Molecular Tumor Boards & Clinical Interpretation Services (HLAAANAD), Pathology Reporting, Synoptic Templates & Cancer Registry Interfaces (HLACAMAJ)

Keywords

• Cancer diagnostic services
• Genomic profiling
• Liquid biopsy testing
• Hematopathology diagnostics
• Hereditary cancer testing

Headquarters

HQ city

Alpharetta

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Cancer Diagnostic Testing Services: CSI Laboratories (now Fulgent Oncology) generates revenue through laboratory diagnostic testing services. The company provides comprehensive cancer testing under one roof, covering the journey from diagnosis to treatment guidance and monitoring. Services include genomic profiling, liquid biopsy, hematopathology evaluation, and hereditary cancer testing. Revenue is generated on a fee-for-service basis, likely through direct billing to healthcare providers, institutions, or insurance payers.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

CSI Laboratories (now Fulgent Oncology) provides comprehensive cancer diagnostic testing services through its Lumera® product line, combining next-generation sequencing with machine learning to deliver personalized genomic insights for solid tumors, hematological malignancies, liquid biopsy, and hereditary cancer risk. Tests are paired with expert clinical case review and consolidated into a single streamlined report for healthcare providers and cancer care teams.

Product overview

CSI Laboratories, now operating as Fulgent Oncology, offers a unified platform of precision medicine solutions for cancer diagnostics through its Lumera® product line. The portfolio combines next-generation sequencing with machine learning capabilities to deliver personalized cancer testing. The product architecture includes dedicated offerings for solid tumor profiling (Lumera® Xpanded Profile, Lumera® NGS Profile, Lumera® Liquid Biopsy), hematopathology analysis (Lumera® Comprehensive Hematological Evaluation, Lumera® Heme NGS Profile), HRR-HRD molecular profiling, and hereditary cancer testing. All tests are summarized in streamlined reports with full clinical case review, providing comprehensive coverage from diagnosis to treatment guidance and monitoring.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

• Comprehensive testing under one roof covering diagnosis to treatment guidance and monitoring

Segments2 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature5 records

Partnerships

One partnership is on record.

• Inform DiagnosticscoreStrategic or Co-development PartnerInform Diagnostics is a subsidiary of Fulgent Genetics, alongside CSI Laboratories. Both organizations are described as leaders in pathology services with more than 50 years of combined experience. They collaborate to provide comprehensive diagnostic services under the Fulgent Oncology brand, enabling advanced cancer testing capabilities.

Scale indicators1 record

Recent moves5 records

Expansion highlights4 records

Direct peers

• Foundation Medicine: Roche-owned NGS-based oncology profiling lab offering FoundationOne CDx and Liquid CDx for solid tumors; the most direct comparable to Fulgent Oncology's Lumera tumor profiling and liquid biopsy menus, serving oncologists and biopharma partners with similar reflex-testing workflows.
• Guardant Health: Specialty oncology lab built around liquid biopsy NGS (Guardant360) and MRD testing; competes head-to-head with the Lumera Liquid Biopsy and solid tumor profiling offerings for US oncology accounts and biopharma companion diagnostic revenue.
• Caris Life Sciences: Precision oncology company providing molecular profiling (Caris Assure, Caris Molecular Intelligence) and AI-driven analytics across solid tumors; directly comparable to Fulgent Oncology's ML-augmented NGS approach and one-stop solid tumor testing strategy.
• Tempus AI: AI-enabled precision medicine company combining NGS profiling, multimodal data, and clinical decision support; the closest peer in combining machine learning with oncology diagnostics and serving both clinician and biopharma customers.
• NeoGenomics: Oncology-focused specialty reference lab providing solid tumor and hematopathology testing services to hospitals, oncologists, and biopharma; a direct competitor across both the solid tumor and hematopathology portions of the Lumera portfolio.
• Natera: Specialty molecular diagnostics lab with oncology franchises in ctDNA MRD testing (Signatera) and hereditary cancer testing (Embrace); overlaps directly with Fulgent Oncology's liquid biopsy / MRD and hereditary cancer testing offerings.
• Personalis: Smaller NGS-based oncology molecular diagnostics company (NeXT Personal, Personalis Dx) competing in tumor profiling and immuno-oncology biomarker testing; comparable in scale and product scope to Fulgent Oncology's NGS tumor profiling menu.
• Myriad Genetics: Established molecular diagnostics company with strong hereditary cancer (BRACAnalysis, MyRisk) and oncology testing franchises; a direct comparable specifically for the hereditary cancer testing segment of Fulgent Oncology's portfolio.
• Adaptive Biotechnologies: Specialty molecular diagnostics company focused on clonoSEQ MRD and immune repertoire sequencing for hematological malignancies; directly comparable to the Lumera Heme NGS and Comprehensive Hematological Evaluation products.

Emerging players

• Pillar Biosciences: Mid-stage NGS oncology testing company focused on targeted tumor profiling panels with biopharma and clinical lab partnerships; overlapping product architecture to Lumera NGS but at smaller scale and with more focus on pharma CDx channels.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/csi-laboratories

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CSI Laboratories